Resverlogix spin-out Zenith Epigenetics raises $8 mln in VC funding
Zenith Epigenetics Corp, a Calgary-based early-stage biotechnology company that last year emerged as the result of RVX Therapeutics Inc's spinout from Resverlogix Corp (TSX: RVX), has obtained US$8 million in financing. The company's investors are Eastern Capital and NGN BioMed Opportunity II, a fund managed by U.S. venture capital firm NGN Capital. Zenith, which is focused on discovering new drugs by leveraging its proprietary epigenetics platform, will use investment proceeds for research and development activities, general expenses, increased working capital and for other corporate purposes. NGN Capital has backed Resverlogix since 2009.
17 March 2014•4 mins read
